GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » Cyclically Adjusted Price-to-FCF

Adhera Therapeutics (Adhera Therapeutics) Cyclically Adjusted Price-to-FCF : (As of May. 14, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adhera Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Adhera Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics Cyclically Adjusted Price-to-FCF Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adhera Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Adhera Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Adhera Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Adhera Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Adhera Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.007/129.8595*129.8595
=-0.007

Current CPI (Sep. 2023) = 129.8595.

Adhera Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 5.412 98.326 7.148
201403 -9.953 99.695 -12.965
201406 -6.902 100.560 -8.913
201409 -8.680 100.428 -11.224
201412 -10.868 99.070 -14.246
201503 -4.061 99.621 -5.294
201506 -2.894 100.684 -3.733
201509 -3.277 100.392 -4.239
201512 -3.600 99.792 -4.685
201603 -0.923 100.470 -1.193
201606 -0.379 101.688 -0.484
201609 -0.175 101.861 -0.223
201612 -0.683 101.863 -0.871
201703 -0.774 102.862 -0.977
201706 -0.758 103.349 -0.952
201709 -0.387 104.136 -0.483
201712 -0.641 104.011 -0.800
201803 -0.112 105.290 -0.138
201806 -7.018 106.317 -8.572
201809 -5.619 106.507 -6.851
201812 -4.827 105.998 -5.914
201903 -3.878 107.251 -4.696
201906 -2.657 108.070 -3.193
201909 -4.904 108.329 -5.879
201912 -4.673 108.420 -5.597
202003 -0.726 108.902 -0.866
202006 -0.177 108.767 -0.211
202009 -0.015 109.815 -0.018
202012 -0.165 109.897 -0.195
202103 -0.082 111.754 -0.095
202106 -0.123 114.631 -0.139
202109 -0.387 115.734 -0.434
202112 -0.345 117.630 -0.381
202203 -0.251 121.301 -0.269
202206 -0.416 125.017 -0.432
202209 -0.211 125.227 -0.219
202212 -0.019 125.222 -0.020
202303 -0.098 127.348 -0.100
202306 -0.003 128.729 -0.003
202309 -0.007 129.860 -0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adhera Therapeutics  (OTCPK:ATRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Adhera Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Adhera Therapeutics (Adhera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.
Executives
Zahed Subhan director 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness director 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: Chief Executive Officer 549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley officer: SVP Finance & Accounting 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan director 812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague officer: Chief Financial Officer C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell director 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato officer: CEO 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris director 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein officer: Chief Legal Officer C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah officer: Chief Financial Officer 10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson officer: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif officer: Chief Operating Officer 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679